«Inflammatory bowel disease (IBD) includes ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis. As these subtypes of IBD display important differences in the behavior of the natural course of the disease, the identification of non-invasive markers for IBD is important.
The aim of the present study was to evaluate the serum levels of 10 adipokines and their association with endoscopic activity in IBD. The 10-protein profile (C-peptide, ghrelin, gastric inhibitory polypeptide, glucagon-like peptide-1, glucagon, insulin, leptin, plasminogen activator inhibitor-1, resistin and visfatin) was evaluated using serum from 53 participants (23 UC and 11 CD patients, as well as 19 controls) from Zacatecas (Mexico) by using the Bio-Plex Pro HumanDiabetes 10-Plex Panel (Bio-Rad Laboratories, Inc.).
Compared with those in the controls, leptin levels were significantly lower in patients with IBD (P=4.9×10−4). In addition, serum leptin displayed differences between groups with and without disease activity on endoscopy (P<0.001). Among the study population, serum leptin levels of <5,494 pg/ml significantly increased the odds of IBD by 12.8-fold [odds ratio (OR)=12.8, 95% confidence interval (CI)=3.04–53.9, P=0.001]. In addition, patients with serum leptin levels of <2,498 pg/ml displayed 5.8-fold greater odds of disease activity on endoscopy among the study population (OR=5.8, 95% CI=1.52–22.4, P=0.013).
No differences in the serum levels of the remaining proteins were identified between the groups. Among the study population, serum leptin was associated with an increasedrisk of IBD and with disease activity on endoscopy. Additional studies will be necessary to validate the use of leptin as a non-invasive biomarker of IBD severity.»
Humans — Not Healthy
Strong Magnitude of Effect.
Comments:«Among the study population, serum leptin was associated with an increasedrisk of IBD and with disease activity on endoscopy. Additional studies will be necessary to validate the use of leptin as a non-invasive biomarker of IBD severity.»
«CONCLUSION: Molecules at the interface between metabolism and immunity such as leptin can either promote an optimal immune response in a balanced metabolic state or, on the other hand, reflect the inappropriate intake of nutrients and associate with abnormal immune response (Figure 3). Until recently, anti-leptin therapy was targeted towards weight regulation. After the discovery of the immune effects of leptin - particularly in inflammation - the development of new therapeutic approaches has been initiated. Many aspects of the biology of leptin remain unclear, and several mechanistic explanations are needed. Yet, the influence of leptin on immunity in relation to the metabolic status can lead to the development of novel approaches that may specifically focus on nutrition for the modulation of the immune response.»
Comments:«Leptin has recently emerged as a key link between metabolic responses and inflammation. It is thought that the elevated levels of leptin in obese individuals can contribute to the low-grade chronic inflammation, on which degenerative diseases and autoimmune reactivity could possibly develop»